Search research articles
Contact Us
Filters
Showing results (41-50 of 64) with videos related to
Page
of 7
Sort By:
Gynecologic Oncology
|
September 18, 2010
Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (VEGF): A Gynecologic Oncology Group Study
Jean A Hurteau, Mark F Brady, Kathleen M Darcy, et al.
Gynecologic Oncology
|
November 19, 2013
Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper
Thomas J Herzog, Deborah K Armstrong, Mark F Brady, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
March 3, 2010
Microscopic observation drug susceptibility assay for tuberculosis screening before isoniazid preventive therapy in HIV-infected persons
Krishna P Reddy, Mark F Brady, Robert H Gilman, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
November 3, 2009
Congenital Trypanosoma cruzi transmission in Santa Cruz, Bolivia
Caryn Bern, Manuela Verastegui, Robert H Gilman, et al.
The New England Journal of Medicine
|
December 30, 2011
Incorporation of bevacizumab in the primary treatment of ovarian cancer
Robert A Burger, Mark F Brady, Michael A Bookman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 19, 2014
Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: A Gynecologic Oncology Group Study
Robert A Burger, Mark F Brady, Michael A Bookman, et al.
Gynecologic Oncology
|
December 3, 2021
Prognostic significance of ethnicity and age in advanced stage epithelial ovarian cancer: An NRG oncology/gynecologic oncology group study
Nefertiti C duPont, Danielle Enserro, Mark F Brady, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 25, 2025
Veliparib concomitant with first-line chemotherapy and as maintenance therapy in ovarian cancer: Final overall survival and disease-related symptoms results
Robert L Coleman, Gini F Fleming, Mark F Brady, et al.
The New England Journal of Medicine
|
March 3, 2016
Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer
John K Chan, Mark F Brady, Richard T Penson, et al.
Gynecologic Oncology
|
March 13, 2021
Correlation of imaging and plasma based biomarkers to predict response to bevacizumab in epithelial ovarian cancer (EOC)
Megan E Buechel, Danielle Enserro, Robert A Burger, et al.
Page
of 7
Search research articles
Search
Showing results (41-50 of 64) with videos related to
Sort By:
Page
of 7
Gynecologic Oncology
|
September 18, 2010
Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (VEGF): A Gynecologic Oncology Group Study
Jean A Hurteau, Mark F Brady, Kathleen M Darcy, et al.
Gynecologic Oncology
|
November 19, 2013
Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper
Thomas J Herzog, Deborah K Armstrong, Mark F Brady, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
March 3, 2010
Microscopic observation drug susceptibility assay for tuberculosis screening before isoniazid preventive therapy in HIV-infected persons
Krishna P Reddy, Mark F Brady, Robert H Gilman, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
November 3, 2009
Congenital Trypanosoma cruzi transmission in Santa Cruz, Bolivia
Caryn Bern, Manuela Verastegui, Robert H Gilman, et al.
The New England Journal of Medicine
|
December 30, 2011
Incorporation of bevacizumab in the primary treatment of ovarian cancer
Robert A Burger, Mark F Brady, Michael A Bookman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 19, 2014
Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: A Gynecologic Oncology Group Study
Robert A Burger, Mark F Brady, Michael A Bookman, et al.
Gynecologic Oncology
|
December 3, 2021
Prognostic significance of ethnicity and age in advanced stage epithelial ovarian cancer: An NRG oncology/gynecologic oncology group study
Nefertiti C duPont, Danielle Enserro, Mark F Brady, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 25, 2025
Veliparib concomitant with first-line chemotherapy and as maintenance therapy in ovarian cancer: Final overall survival and disease-related symptoms results
Robert L Coleman, Gini F Fleming, Mark F Brady, et al.
The New England Journal of Medicine
|
March 3, 2016
Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer
John K Chan, Mark F Brady, Richard T Penson, et al.
Gynecologic Oncology
|
March 13, 2021
Correlation of imaging and plasma based biomarkers to predict response to bevacizumab in epithelial ovarian cancer (EOC)
Megan E Buechel, Danielle Enserro, Robert A Burger, et al.
Page
of 7